Search results
Results from the WOW.Com Content Network
Survodutide (BI 456906) is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin .
The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will ...
Survodutide “has significant potential to make a meaningful difference to people living with cardiovascular, renal and metabolic conditions,” said Dr. Waheed Jamal, Boehringer Ingelheim’s ...
German drugmaker Boehringer Ingelheim said it hopes that drug candidate survodutide, co-developed to treat obesity and fatty liver with Zealand Pharma, could be launched in 2027 or 2028 ...
2740 14652 Ensembl ENSG00000112164 ENSMUSG00000024027 UniProt P43220 O35659 RefSeq (mRNA) NM_002062 NM_021332 RefSeq (protein) NP_002053 NP_067307 Location (UCSC) Chr 6: 39.05 – 39.09 Mb Chr 17: 31.12 – 31.16 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Survodutide is unique because it uses a mechanism of action (the GLP-1 receptor) that partially overlaps with the products on the market made by Eli Lilly and Novo Nordisk, but it also targets the ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us